Denis Larsimont
About
In The Last Decade
Denis Larsimont
267 papers receiving 12.6k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 7.3k
- Cancer Research 5.3k
- Molecular Biology 4.8k
- Pulmonary and Respiratory Medicine 2.0k
- Radiology, Nuclear Medicine and Imaging 1.5k
Countries citing papers authored by Denis Larsimont
This map shows the geographic impact of Denis Larsimont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Larsimont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Larsimont more than expected).
Fields of papers citing papers by Denis Larsimont
This network shows the impact of papers produced by Denis Larsimont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Larsimont. The network helps show where Denis Larsimont may publish in the future.
Co-authorship network of co-authors of Denis Larsimont
This figure shows the co-authorship network connecting the top 25 collaborators of Denis Larsimont. A scholar is included among the top collaborators of Denis Larsimont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Larsimont. Denis Larsimont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | 2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC) | Immuno-Oncology Technology | Isabelle Desmoulins, Emanuela Romano et al. | 0 |
| 2 | Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. | Journal of Clinical Oncology | David Venet, Ghizlane Rouas et al. | 2 |
| 3 | PIK3CAcopy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer | Molecular Case Studies | Ottavia Amato, Laurence Buisseret et al. | 5 |
| 4 | Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers | Frontiers in Oncology | Ali Bohlok, François Richard et al. | 4 |
| 5 | Effectiveness of Carbon Localization for Invasive Breast Cancer: An Institutional Experience | The Breast Journal | Michel Moreau, Denis Larsimont et al. | 0 |
| 6 | Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse | JCO Precision Oncology | Elisa Agostinetto, Matteo Lambertini et al. | 48 |
| 7 | Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer | Clinical Cancer Research | François Richard, Samira Majjaj et al. | 19 |
| 8 | Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer | BMJ Open Gastroenterology | Pieter Demetter, María Gómez Galdón et al. | 4 |
| 9 | Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study | JMIR Research Protocols | Gabriel Liberale, Sophie Vankerckhove et al. | 7 |
| 10 | Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis | PubMed | Christiane Jungels, Denis Larsimont et al. | 1 |
| 11 | DNA methylation–based immune response signature improves patient diagnosis in multiple cancers | Journal of Clinical Investigation | Jana Jeschke, Martin Bizet et al. | 110 |
| 12 | Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis | PLoS ONE | Hatem A. Azim, Sandeep K. Singhal et al. | 3 |
| 13 | Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel | Clinical Cancer Research | Carlos M. Galmarini, Isabelle Treilleux et al. | 55 |
| 14 | Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures | Breast Cancer Research and Treatment | Christos Sotiriou, Benjamin Haibe‐Kains et al. | 2 |
| 15 | Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel | Cancer Research | Christine Desmedt, Virginie Durbecq et al. | 40 |
| 16 | HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. | PubMed | Angelo Di Leo, David Gancberg et al. | 216 |
| 17 | HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. | PubMed | Denis Larsimont, Angelo Di Leo et al. | 11 |
| 18 | Ganglion sentinelle et cancer invasif du sein: vers une nouvelle approche chirurgicale minimaliste. | Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) | Jean‐Marie Nogaret, Dina Hertens et al. | 0 |
| 19 | Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer | Breast Cancer Research and Treatment | Fátima Cardoso, Angelo Di Leo et al. | 2 |
| 20 | Preoperative Axillary Immunolymphoscintigraphy (ilsc) in Breast-cancer Patients Using a 123-iodine Labeled Monoclonal-antibody (ab) | European Journal of Nuclear Medicine and Molecular Imaging | J Frühling, Denis Larsimont et al. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.